[1]刘振亚,赵慧敏,王临艳.血清淀粉样蛋白A 与肿瘤诊断、分期和预后相关性研究进展[J].现代检验医学杂志,2023,38(03):207-212.[doi:10.3969/j.issn.1671-7414.2023.03.039]
　LIU Zhen-ya,ZHAO Hui-min,WANG Lin-yan.Advances on the Correlation between Serum Amyloid A and Cancer Diagnosis, Stage and Prognosis[J].Journal of Modern Laboratory Medicine,2023,38(03):207-212.[doi:10.3969/j.issn.1671-7414.2023.03.039]
点击复制

血清淀粉样蛋白A 与肿瘤诊断、分期和预后相关性研究进展()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年03期
页码:
207-212
栏目:
综述
出版日期:
2023-05-15

文章信息/Info

Title:
Advances on the Correlation between Serum Amyloid A and Cancer Diagnosis, Stage and Prognosis
文章编号:
1671-7414（2023）03-207-06
作者:
刘振亚; 赵慧敏; 王临艳
（甘肃省妇幼保健院，兰州730050）
Author(s):
LIU Zhen-ya;  ZHAO Hui-min;  WANG Lin-yan
（Maternal and Child Health Hospital of Gansu Province，Lanzhou 730050，China）
关键词:
血清淀粉样蛋白A（SAA）; 肿瘤; 生物标志物
分类号:
R730.43
DOI:
10.3969/j.issn.1671-7414.2023.03.039
文献标志码:
A
摘要:
目前用于肿瘤诊断和肿瘤分期的方法多具有侵袭性，且部分肿瘤标志物敏感性较低，已不能满足临床需求。已有大量的研究表明：血清淀粉样蛋白A(serum amyloid A, SAA) 与多种肿瘤的发生、发展密切相关，有较高的敏感度和特异度，无侵袭性、操作简单和成本低等优点。SAA 联合其他肿瘤标志物及肿瘤检测方法在肿瘤诊断、病理分期和预后判定中发挥临床价值。该文就近年来SAA 在多种肿瘤中的研究进展进行综述，为肿瘤患者个体化精准治疗、提升治疗效果、提高生存质量、提供理论支持。
Abstract:
At present, most of the methods used for tumor diagnosis and tumor staging are invasive, and some tumor markers have low sensitivity and have been unable to meet the clinical needs. A large number of studies have shown that serum amyloid A (SAA) is closely related to the occurrence and development of a variety of tumors, and has a high sensitivity and specificity, and whether invasive, simple operation and low cost, combined with other tumor markers and tumor detection methods play a clinical value in tumor diagnosis, pathological staging and prognosis. This article reviews the research of SAA in a variety of tumors in recent years, providing theoretical support for individualized precise treatment of cancer patients, improving the therapeutic effect, and improving the quality of life.

参考文献/References:

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer Journal Clinical,2021,71(3): 209-249.
[2] SHIMADA H, NOIE T, OHASHI M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association[J]. Gastric Cancer, 2014,17(1): 26-33.
[3] 李福刚, 雷蕾, 石晓强, 等. 血清淀粉样蛋白 A(SAA) 水平检测在临床实验诊断及健康监测中的 应用[J]. 现代检验医学杂志, 2019,34(3): 1-5. LI Fugang,LEI Lei,SHI Xiaoqiang, et al.Serum amyloid A (SAA) test in clinical diagnosis and health monitoring[J].Journal of Modern Laboratry Medicine,2019, 34(3): 1-5.
[4] DE BUCK M, COUWY M, WANG Jiming, et al. Structure and Expression of different serum amyloid A (SAA) vari- ants and their concentration-dependent functions during host insults[J]. Current Medicinal Chemistry, 2016, 23(17): 1725-1755.
[5] KLUVE-BECKERMAN B, DRUMM M L, BENSON M D. Nonexpression of the human serum amyloid A three (SAA3) gene[J]. DNA Cell Biol, 1991, 10(9): 651-661.
[6] LARSON M A, WEI S H, WEBER A, et al. Induction of human mammary-associated serum amyloid A3 expression by prolactin or lipopolysaccharide[J]. Biochem Biophys Res Commun, 2003, 301(4): 1030- 1037.
[7] TAMAMOTO T, OHNO K, GOTO-KOSHINO Y, et al. Serum amyloid A promotes invasion of feline mammary carcinoma cells[J]. J Vet Med Sci, 2014,76(8): 1183- 1188.
[8] ALONZI T, MARITANO D R, GORGONI B, et al. Essential role of STAT3 in the control of the acutephase response as revealed by inducible gene activation in the liver[J]. Molecular and Cellular Biology, 2001,21(5): 1621-1632.
[9] KUSHNER I.The acute phase response: an overview[J]. Methods Enzymol, 1988,163: 373-383.
[10] REN Peng, SUN Deshun, XIN Dajing, et al. Serum amyloid A promotes osteosarcoma invasion via upregulating α v β 3 integrin[J]. Molecular Medicine Reports, 2014,10(6): 3106-3112.
[11] ZHANG Yan, ZHANG Jie, SHENG Huiming, et al. Acute phase reactant serum amyloid A in inflammation and other diseases[J]. Adv Clin Chem, 2019, 90: 25-80.
[12] 中国妇幼保健协会临床诊断与实验医学分会, 柯 江维, 徐锦, 等. SAA 单独和与CRP 联合检测在 儿童感染性疾病中的应用专家共识[J]. 检验医学,2021,36(7): 685-690. Clinical Diagnosis and Laboratory Medicine Branch of China Maternal and Child Health Association,KE Jiangwei, XU Jin, et al. Expert consensus on the application of SAA alone and in combination with CRP in infectious diseases in children[J]. Laboratory Medicine, 2021, 36(7): 685-690.
[13] RONG Biaoxue, LIU Hua, GAO Wenlong, et al. Increased serum amyloid A as potential diagnostic marker for lung cancer: a meta-analysis based on nine studies[J]. BMC Cancer, 2016,16(1): 836.
[14] 王君, 张玉凤, 姜芹. 肺癌患者血清淀粉样蛋白 A(SAA) 水平及临床意义[J]. 临床肺科杂志, 2018,23(8): 1516-1519. WANG Jun,ZHANG Yufeng,JIANG Qin.Serum amyloid A(SAA) level in patients with lung cancer and its clinical significance[J]. Journal of Clinical Pulmonary Medicine,2018, 23(8): 1516-1519.
[15] SUNG H J, AHN J M, YOON Y H, et al. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer[J]. Journal of Proteome Research, 2011,10(3): 1383-1395.
[16] LIN Haiyingjie, TAN Guoqiang, LIU Yan, et al. The prognostic value of serum amyloid A in solid tumors: a meta-analysis[J]. Cancer Cell Int, 2019,19: 62.
[17] CHO W C, YIP T T, CHENG W W, et al. Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis[J]. Br J Cancer,2010,102(12): 1731-1735.
[18] LIAO Qiulin, ZHAO Liang, CHEN Xiaodong, et al. Serum proteome analysis for profiling protein markers associated with carcinogenesis and lymph node metastasis in nasopharyngeal carcinoma[J]. Clin Exp Metastasis, 2008,25(4): 465-476.
[19] CHO W C, YIP T T, YIP C, et al. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling[J]. Clin Cancer Res, 2004,10(1 Pt 1): 43-52.
[20] CHEN Qiuyan, TANG Qingnan, TANG Linquan, et al. Pretreatment serum amyloid A and c-reactive protein comparing with epstein-barr Virus DNA as prognostic indicators in patients with nasopharyngeal carcinoma: a prospective study[J]. Cancer Research and Treatment,2018,50(3): 701-711.
[21] LI Jianpei, LAI Changchun, PENG Songguo, et al. The prognostic value of integration of pretreatment serum amyloid A (SAA)–EBV DNA (S‐D) grade in patients with nasopharyngeal carcinoma[J]. Clinical and Translational Medicine, 2020,9(1): 2.
[22] LUNG H L, MAN O Y, YEUNG M C, et al. SAA1 polymorphisms are associated with variation in antiangiogenic and tumor-suppressive activities in nasopharyngeal carcinoma[J]. Oncogene, 2015,34(7): 878-889.
[23] 李筱, 张静, 向慧敏. 血浆长链非编码RNA ATB 联合MMP-1 与SAA 在食管癌中的临床价值研究[J].实用癌症杂志, 2019, 34 (8 ): 1244-1249, 1260. LI Xiao, ZHANG Jing, XIANG Huimin. Clinical Value of Long Non-coding RNA ATB combined with MMP- 1 and SAA in esophageal carcinoma[J]. The Practical Journal of Cancer,2019,34(8): 1244-1249, 1260.
[24] WANG Junye, ZHENG Yuzhen, YANG Juan, et al. Elevated levels of serum amyloid A indicate poor prognosis in patients with esophageal squamous cell carcinoma[J]. BMC Cancer, 2012,12: 365.
[25] 胡勇, 刘亚军, 张强, 等. 血清淀粉样蛋白A 对食管癌再程放疗患者预后的影响[J]. 中国肿瘤临床与康复, 2021,28(4): 439-442. HU Yong , LIU Yajun , ZHANG Qiang ,et al. Serum amyloid A and prognosis of esophageal cancer on reirradiation[J].Chin J Clin Oncol Rehabil, 2021,28(4): 439-442.
[26] 刘池波, 梁勇, 王海宝, 等. 胃癌患者中血清淀粉样蛋白A 的测定及临床意义[J]. 中华胃肠外科杂志,2009, 12(3): 314-315.. LIU ChiBo, LIANG Yong, WANG Haibao, et al,Determination and clinical significance of serum amyloid albumen A in patients with gastric cancer[J]. Chin J G astIointest Surg,2009,12(3): 314-315.
[27] YASUKAWA Y, HATTORI N, IIDA N, et al. SAA1 is upregulated in gastric cancer-associated fibroblasts possibly by its enhancer activation[J]. Carcinogenesis,2021,42(2): 180-189.
[28] FIRPO M A, GAY D Z, GRANGER S R, et al. Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen[J]. World J Surg, 2009,33(4): 716-722.
[29] 陈国利, 羿海钊, 王建利. 血清PCT, SAA, CRP,ALB 对胰腺癌术后胰瘘的诊断价值[J]. 河北医学,2022,28(5): 853-857. CHEN Guoli, YI Haizhao, WANG Jianli. Diagnostic value of the change of serum PCT, SAA, CRP and ALB in pancreatic fistula after surgery for pancreatic cancer[J]. Hebei Medicine, 2022, 28(5): 853-857.
[30] TAKEHARA M, SATO Y, KIMURA T, et al. Cancerassociated adipocytes promote pancreatic cancer progression through SAA1 expression[J]. Cancer Science, 2020,111(8): 2883-2894.
[31] DJUREC M, GRANA O, LEE A, et al. SAA3 is a key mediator of the protumorigenic properties of cancerassociated fibroblasts in pancreatic tumors[J]. Proc Natl Acad Sci U S A, 2018,115(6): E1147-E1156.
[32] NI Xiaochun, YI Yong, FU Yipeng, et al. Serum amyloid A is a novel prognostic biomarker in hepatocellular carcinoma[J]. Asian Pacific Journal of Cancer Prevention, 2015,15(24): 10713-10718.
[33] ZHANG Wei, KONG Huifang, GAO Xudong, et al. Immune infiltration-associated serum amyloid A1 predicts favorable prognosis for hepatocellular carcinoma[J]. World Journal of Gastroenterology,2020,26(35): 5287-5301.
[34] GLOJNARIC I, CASL M T, SIMIC D, et al. Serum amyloid A protein (SAA) in colorectal carcinoma[J]. Clin Chem Lab Med, 2001,39(2): 129-133.
[35] YANG Qinghua, SUN Chengcheng, ZHAO Lisha. Expression and predictive value of serum NLR, PLR combined with SAA in patients with different stages of colorectal cancer[J]. Frontiers in Surgery, 2022, 9: 906074.
[36] DAVIS T A, CONRADIE D, SHRIDAS P, et al. Serum amyloid a promotes inflammation-associated damage and tumorigenesis in a mouse model of colitis-associated cancer[J]. Cellular and Molecular Gastroenterology and Hepatology, 2021,12(4): 1329- 1341.
[37] 雷建梅, 匡文斌, 邓秋婵, 等. 血清HIF-1α, 25（OH）D3, IGF-1 及SAA 水平在不同临床特征乳腺癌患者中的表达及临床意义[J]. 中国医学创新,2021,18(34): 48-52. LEI Jianmei,KUANG Wenbin, DENG Qiuchan, et al. Expression and clinical significance of levels of HIF- 1α, 25 (OH) D3, IGF-1 and SAA in breast cancer patients with different clinical characteristics[J].Medical Innovation of China, 2021,18(34): 48-52.
[38] ZHANG Guojun, SUN Xudong, L? Hong, et al. Serum amyloid A: A new potential serum marker correlated with the stage of breast cancer[J]. Oncol Lett,2012,3(4): 940-944.
[39] PLESSIS M, DAVIS T A, OLIVIER D W, et al. A functional role for serum amyloid A in the molecular regulation of autophagy in breast cancer[J]. Frontiers in Oncology, 2022,12(10): 925-944.
[40] URIELI-SHOVAL S, FINCI-YEHESKEL Z, DISHON S, et al. Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis[J]. Journal of Histochemistry & Cytochemistry, 2010,58(11): 1015-1023.
[41] LI Ze, HOU Yongwang, ZHAO Meng, et al. Serum amyloid A, a potential biomarker both in serum and tissue, correlates with ovarian cancer progression[J]. Journal of Ovarian Research, 2020,13(1): 67.
[42] CHOI H, IGNACIO R M C, LEE E, et al. Augmented serum amyloid A1/2 mediated by TNF-induced NF-κB in human serous ovarian epithelial tumors[J]. Immune Network, 2017,17(2): 121.
[43] COCCO E, BELLONE S, EL-SAHWI K, et al. serum amyloid A (SAA): a novel biomarker for endometrial[J]. Cancer, 2010,116(4): 843-851.
[44] OMER B, GENC S, TAKMAZ O, et al. The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients[J]. Tumor Biology, 2013,34(5): 2645-2650.
[45] 陶小枫, 王晓希, 刘维, 等. 血清IL-6, SAA 及PSA 检测对前列腺癌的诊断价值[J]. 山西医科大学学报,2019,50(01): 70-74. TAO Xiaofeng, WANG Xiaoxi, LIU Wei, et al. Diagnostic value of serum IL-6, SAA and PSA for prostate cancer[J].J Shanxi Med Univ,2019,50(1): 70-74.
[46] 陈维真, 张勇, 罗辉. SAA 与前列腺癌病理分级和临床分期的关系[J]. 当代医学, 2010,16(25): 16-17. CHEN Weizhen, ZHANG Yong, LUO Hui. Relationship between SAA and pathological grade and clinical stage of prostate cancer[J]. Contemporary Medicine,2010, 16(25):16-17.
[47] 程清, 杨涛, 尹全乐. 血清前列腺特异性抗原同源异构体2 及淀粉样蛋白A 对前列腺癌的诊断价值[J].山西医药杂志, 2020,49(19): 2649-2650. CHEN Qing,YANG Tao,YING Quanle.Diagnostic value of serum prostate-specific antigen homologous isomer 2 and amyloid protein a in prostate cancer[J]. Shanxi Med J,2020,49(19): 2649-2650.
[48] KIMURA M, TOMITA Y, IMAI T, et al. Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma[J]. Cancer, 2001,92(8): 2072-2075.
[49] FISCHER K, THEIL G, HODA R, et al. Serum amyloid A: a biomarker for renal cancer[J]. Anticancer Res,2012,32(5): 1801-1804.
[50] OZ ATALAY F, AYTAC VURUSKAN B, VURUSKAN H. Significance of amyloid A immunoexpression in the prognosis of renal cell carcinoma[J]. APMIS,2016,124(4): 257-262.
[51] WAN-IBRAHIM W I, ASHRAFZADEH A, SINGH V A, et al. Contrasting increased levels of serum amyloid A in patients with three different bone sarcomas: An indicator of tumor malignancy?[J]. Electrophoresis,2016,37(17/18): 2328-2337.
[52] REN Peng, SUN Deshun, XIN Dajing, et al. Serum amyloid A promotes osteosarcoma invasion via upregulating α v β 3 integrin[J]. Mol Med Rep, 2014,10(6): 3106-3112.
[53] KNEBEL F H, UNO M, GALATRO T F, et al. Serum amyloid A1 is upregulated in human glioblastoma[J]. Journal of Neuro-Oncology, 2017,132(3): 383-391.
[54] CAO Kangxi, JIANG Xingyu, WANG Baishun, et al. SAA1 expression as a potential prognostic marker of the tumor microenvironment in glioblastoma[J]. Front Neurol, 2022, 13: 905561.
[55] ZHANG Huikai, XU Yang, DENG Gang, et al. SAA1 knockdown promotes the apoptosis of glioblastoma cells via downregulation of AKT signaling[J]. J Cancer, 2021,12(9): 2756-2767.

相似文献/References:

[1]祖瑞铃,叶波.不同肿瘤与并发胰腺炎患者血清AMY和LPS的分布水平及实验诊断价值研究[J].现代检验医学杂志,2019,34(01):76.[doi:10.3969/j.issn.1671-7414.2019.01.019]
　ZU Rui-ling,YE Bo.Distributions and Diagnostic Values of Serum Amylase and Lipase in Patients with Various Types of Tumors and Those with Pancreatitis[J].Journal of Modern Laboratory Medicine,2019,34(03):76.[doi:10.3969/j.issn.1671-7414.2019.01.019]
[2]王李秦,魏绪仓.Galectin-4与肿瘤相关性的研究进展[J].现代检验医学杂志,2019,34(01):161.[doi:10.3969/j.issn.1671-7414.2019.01.042]
　WANG Li-qin,WEI Xu-cang.Research of Galectin-4 in Tumor[J].Journal of Modern Laboratory Medicine,2019,34(03):161.[doi:10.3969/j.issn.1671-7414.2019.01.042]
[3]左二冬,代　卫,陆　晔,等.放疗相关性贫血患者血清Hepcidin，EPO 表达特征[J].现代检验医学杂志,2020,35(02):43.[doi:10.3969/j.issn.1671-7414.2020.02.013]
　ZUO Er-dong,DAI Wei,LU Ye,et al.Expression Features of Serum Hepcidin and EPO in Tumor Patients withRadiotherapy-Related Anemia[J].Journal of Modern Laboratory Medicine,2020,35(03):43.[doi:10.3969/j.issn.1671-7414.2020.02.013]
[4]王秋云,严　敏,程　珍,等.肿瘤及血液病患者血清 sTRAIL表达及与 IL-6和 Hepcidin水平的相关性研究[J].现代检验医学杂志,2021,36(01):58.[doi:10.3969/j.issn.1671-7414.2021.01.015]
　WANG Qiu-yun,YAN Min,CHENG Zhen,et al.Study of the Expression of the Serum sTRAIL, and Its Correlation with Levels of Serum IL-6 and Hepcidin in the Patients with the Tumor and Hematological Diseases[J].Journal of Modern Laboratory Medicine,2021,36(03):58.[doi:10.3969/j.issn.1671-7414.2021.01.015]
[5]夏艳艳,沈　瀚,许红攀,等.液体活检技术在肿瘤诊断中的最新研究进展[J].现代检验医学杂志,2021,36(03):157.[doi:10.3969/j.issn.1671-7414.2021.03.037]
　XIA Yan-yan,SHEN Han,XU Hong-pan,et al.Latest Research Progress of Liquid Biopsy in Tumor Diagnosis[J].Journal of Modern Laboratory Medicine,2021,36(03):157.[doi:10.3969/j.issn.1671-7414.2021.03.037]
[6]刘　霄a,黄晓燕b,王建华a.长链非编码RNASNHG9在不同肿瘤中的最新研究进展[J].现代检验医学杂志,2021,36(04):176.[doi:10.3969/j.issn.1671-7414.2021.04.038]
　LIU Xiaoa,HUANG Xiao-yanb,WANG Jian-huaa.Reasearch Progress of Long Non-coding RNA SNHG9 in Different Tumors[J].Journal of Modern Laboratory Medicine,2021,36(03):176.[doi:10.3969/j.issn.1671-7414.2021.04.038]
[7]刁 迅,范绮雨,耿良栋,等.基于生物信息学分析双硫死亡相关基因PDLIM1 mRNA在多种肿瘤中的表达及临床应用价值[J].现代检验医学杂志,2024,39(01):36.[doi:10.3969/j.issn.1671-7414.2024.01.007]
　DIAO Xun,FAN Qiyu,GENG Liangdong,et al.Analysis of Expression in Disulfidptosis-Related Gene PDLIM1 mRNA in Various Tumors and Its Clinical Application Value Based on Bioinformatics[J].Journal of Modern Laboratory Medicine,2024,39(03):36.[doi:10.3969/j.issn.1671-7414.2024.01.007]

备注/Memo

备注/Memo:
基金项目：甘肃省科学技术厅自然科学基金项目（20JR10RA424）。
作者简介：刘振亚（1989-），女，硕士，主管检验师，研究方向：临床检验诊断学，E-mail: lzya1989@126.com。
通讯作者：王临艳（1974-），女，本科，副主任检验师，研究方向：临床检验诊断学，E-mail: wlyan1974@163.com。
更新日期/Last Update: 2023-05-15